You are here: Industry Insights > Arthritis

News List

Experimental Drug Could Be New Option Against Arthritis drugs
January 02, 2020
A new drug might be able to save a person's knees from the ravages of osteoarthritis, researchers report.
Serum IL-35 Levels Tied to Bone Loss With Rheumatoid Arthritis drugs
September 27, 2019
Serum interleukin (IL)-35 levels are associated with bone loss and may represent a novel therapeutic target for postmenopausal women with rheumatoid arthritis (RA) ...
Janssen Submits TREMFYA Application to FDA for Psoriatic Arthritis americanpharmaceuticalreview
September 18, 2019
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking ...
Ultrasonography Helps Differentiate Arthritis Types drugs
September 04, 2019
Ultrasound is effective for differentiating between the major types of arthritis when combined with a physical exam and patient history, according to a review recently published in The Open Medical Imaging Journal.
Amgen to acquire Otezla® for $13.4 billion in cash worldpharmanews
August 27, 2019
Amgen announced today that it has entered into an agreement with Celgene Corporation in connection with its previously announced merger with Bristol-Myers Squibb Company to acquire...
Antibiotic Use Tied to Higher Risk of Rheumatoid Arthritis drugs
August 26, 2019
Antibiotic prescriptions are associated with a higher risk of rheumatoid arthritis (RA), according to a study published online in BMC Medicine.
RINVOQ™ arthritis treatment granted approval by FDA europeanpharmaceuticalreview
August 20, 2019
The FDA has given its approval to RINVOQ for the treatment of active rheumatoid arthritis after the drug reached its endpoints in clinical trials.
FDA Approves Rinvoq (upadacitinib), an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rheumatoid Arthritis drugs
August 19, 2019
AbbVie, a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor...
Cancer Risks Examined in Rheumatoid Arthritis Patients drugs
July 25, 2019
Compared with the general population, there is an increased risk for certain cancers in patients with rheumatoid arthritis (RA) in Singapore...
Filgotinib Bests Placebo in Tx of Refractory Rheumatoid Arthritis drugs
July 24, 2019
Among patients with moderately to severely active rheumatoid arthritis (RA) resistant to previous therapy with biologic agents...

Previous page 1 2 3 4 Next page